News Release
- 2022.10.28 Research and Development
- Notification of the Results of the Phase III Clinical Study of HP-5000 for Osteoarthritis Pain of the Knee in the U.S. (Pain Relief and Anti-Inflammatory Patch)
- 2022.10.12 lR Information
- FY02/2023 Q2 Results Earnings Release Presentation
- 2022.10.12 lR Information
- Notification Regarding Concerning the Decision of Matters Relating to Acquisition of Company’s Own Shares
- 2022.09.16 Sustainability
- Notice regarding Support for The Disaster of The Torrential Rains from August 3, 2022
- 2022.07.25 lR Information
- Notice regarding Determination of Details of Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
- 2022.07.07 lR Information
- Notice regarding Issuance of Stock Compensation-Type Share Options (Stock Acquisition Rights)
- 2022.07.07 lR Information
- FY02/2023 Q1 Results Earnings Release Presentation
- 2022.05.26 Management and Personnel
- Executive Appointments
- 2022.05.18 Other
- Salonpas® Named the World’s No.1 OTC Topical Analgesic Patch Brand for the Sixth Consecutive Year
- 2022.04.21 Research and Development
- Notification of application for manufacturing and marketing approval of HP-5070 (primary palmar hyperhidrosis treatment drug) in Japan
- 2022.04.07 Sustainability
- Notice regarding humanitarian support for Ukraine
- 2022.04.07 Management and Personnel
- Executive Appointments
- 2022.04.07 lR Information
- FY02/2022 Q4 Results Earnings Release Presentation
- 2022.03.31 Other
- Acquisition of Shares of AYM HD
- 2022.03.23 lR Information
- Notice regarding Revision of Earnings Forecast
- 2022.03.23 Subsidiaries and Affiliated Companies
- Noven Pharmaceuticals, Inc. press release : FDA Approves Once-Daily XELSTRYM™ (dextroamphetamine) Transdermal System, CII, for the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults and Pediatric Patients 6 Years and Older
- 2022.01.14 lR Information
- Notice regarding Results and Completion of Acquisition of Treasury Shares
- 2022.01.13 lR Information
- FY02/2022 Q3 Results Earnings Release Presentation
